Verition Fund Management
VYGR icon

Verition Fund Management’s Voyager Therapeutics VYGR Stock Holding History

Verition Fund Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,450
Closed -$76.3K – 3750
2024
Q4 		$76.3K Sell
13,450
-23,556
-64% -$152K ﹤0.01% 3104
2024
Q3 		$216K Buy
+37,006
New +$269K ﹤0.01% 2837

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management's VYGR Position: Q1 2025 in Review

Verition Fund Management sold out of Voyager Therapeutics (VYGR) in Q1 2025, closing a stake of 13,450 shares — an estimated $76.3K sold.

Verition Fund Management first reported a position in VYGR in Q3 2024 and held it in 2 quarters. The position peaked at $216K in Q3 2024. 116 funds tracked by Wall St. Rank hold VYGR as of Q1 2025.

  • Verition Fund Management reported no remaining Voyager Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 13,450 Voyager Therapeutics shares in Q1 2025, an estimated $76.3K.
  • Verition Fund Management first reported a position in Voyager Therapeutics in Q3 2024 and held it in 2 quarters.
  • Verition Fund Management's Voyager Therapeutics position peaked at $216K in Q3 2024.
  • 116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.